2 Discovery of Cep-1347/Kt-7515, an Inhibitor of the Jnk/Sapk Pathway for the Treatment of Neurodegenerative Diseases

Michael S. Saporito(Teva Pharmaceuticals (United States)), Anna C. Maroney(Brandywine Photonics (United States)), Robert L. Hudkins(State Street (United States))

Progress in medicinal chemistry

January 1, 2002

10.1016/s0079-6468(08)70081-x

Cited by 98

Related Papers

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

|ACS Chemical Neuroscience|2011|436

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

|PubMed|2003|124

Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives

|Journal of Medicinal Chemistry|1997|120

Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors

|Expert Opinion on Drug Discovery|2016|113

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

|Molecular Cancer Therapeutics|2007|112